References
- Cancer Research UK. Hodgkin lymphoma incidence statistics. Cancer Research UK Cancer statistics. http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/hodgkin-lymphoma/incidence. Accessed July 6, 2015
- ISD Scotland. Scottish Cancer Registry. Scottish Cancer Registry Cancer Statistics Hodgkin Lymphoma. http://www.isdscotland.org/Health-Topics/Cancer/Cancer-Statistics/Hodgkins-Disease/. Accessed July 6, 2015
- European Medicines Agency. Public summary of opinion on orphan designation. EU/3/08/596. 2015. http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2009/10/WC500006354.pdf. Accessed March 17, 2016
- Eichenauer DA, Engert A, Dreyling M. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011;22(Suppl 6):vi55-8
- Specht L, Gray RG, Clarke MJ, et al. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin's Disease Collaborative Group. J Clin Oncol 1998;16:830-43
- Crump M. Management of Hodgkin lymphoma in relapse after autologous stem cell transplant. Hematol Am Soc Hematol Educ Program 2008:326-33
- Arai S, Fanale M, deVos S, et al. Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. Leuk Lymphoma 2013;54:2531-3
- Horning S, Fanale M, deVos S, et al. Defining a population of Hodgkin lymphoma patients for novel therapeutics: an international effort. Ann Oncol 2008;19:abstract 118.
- Martinez C, Canals C, Sarina B, et al. Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation. Ann Oncol 2013;24:2430-34
- Seattle Genetics, Inc. ADCETRIS® (brentuximab vedotin) for Injection. Full prescribing information. Food and Drug Administration. http://www.adcetris.com/pdf/ADCETRIS-brentuximab-vedotin-Prescribing-Information.pdf. Accessed July 6, 2015
- Takeda Pharma A/S. ADCETRIS® 50 mg powder for concentrate for solution for infusion. Summary of Product Characteristics. European Medicines Agency. https://www.medicines.org.uk/emc/medicine/27173. Accessed July 6, 2015
- Chen R, Gopal AK, Smith SE, et al. Five-year survival data demonstrating durable responses from a pivotal phase 2 study of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood 2015;126:2736
- Gopal AK, Chen R, Smith SE, et al. Three-year follow-up data and characterization of long-term remissions from an ongoing phase 2 study of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood 2013;122:abstract 4382
- Gopal AK, Chen R, Smith SE, et al. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood 2015;125:1236-43
- Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol 2012;30:2183-9
- National Institute for Health and Care Excellence. Brentuximab vedotin for treating CD30-positive Hodgkin's lymphoma after autologous stem cell transplant. Proposed Health Technology Appraisal. National Institute for Health and Care Excellence Proposed Health Technology Appraisal. https://www.nice.org.uk/guidance/gid-tag467/documents/lymphoma-hodgkins-cd30positive-brentuximab-vedotin-after-autologous-stem-cell-transplant-draft-scope-for-consultation-prereferral-november-2013-2. Accessed July 6, 2015
- Scottish Medicines Consortium (SMC). Brentuximab vedotin (ADCETRIS®) 50mg powder for concentrate for solution for infusion. SMC No (989/14). https://www.scottishmedicines.org.uk/files/advice/DAD_brentuximab_vedotin__Adcetris__FINAL_Sept_2014_for_website.pdf. Accessed July 6, 2015
- Scottish Medicines Consortium. Guidance to manufacturers for completion of New Product Assessment Form (NPAF). https://www.scottishmedicines.org.uk/Submission_Process/Submission_guidance_and_forms/Templates-Guidance-for-Submission. Accessed July 4, 2016
- Sarina B, Castagna L, Farina L, et al. Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood 2010;115:3671-7
- Cavalieri E, Matturro A, Annechini G, et al. Efficacy of the BEACOPP regimen in refractory and relapsed Hodgkin lymphoma. Leuk Lymphoma 2009;50:1803-8
- El GT, Dupuis J, Belhadj K, et al. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol 2007;18:1363-8
- Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009;27:4378-84
- Moskowitz AJ, Perales MA, Kewalramani T, et al. Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma. Br J Haematol 2009;146:158-63
- Ng M, Waters J, Cunningham D, et al. Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma. Br J Cancer 2005;92:1352-7
- Selby P, Patel P, Milan S, et al. ChlVPP combination chemotherapy for Hodgkin's disease: long-term results. Br J Cancer 1990;62:279-85
- Walewski AJ, Romejko-Jarosinska A, Zwolinski J. DHAP Chemotherapy for recurrent/refractory lymphoma – Five year follow up of 112 patients. Proc Am Soc Clin Oncol 2001;abstract 20
- Robinson SP, Sureda A, Canals C, et al. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome. Haematologica 2009;94:230-8
- Martinez C. Relapse of Hodgkin’s lymphoma after autologous stem cell transplantation (ASCT): Identification of prognostic factors predicting outcome. Oral presented at the 8th International Symposium on Hodgkin Lymphoma, Cologne, Germany, October 23?26, 2010. http://www.informed-scientist.org/presentation/relapse-of-hodgkin-s-lymphoma-after-autologous-stem-cell-transplantation-asct-identification-of-prognostic-factors-predicting-outcome. Accessed July 4, 2016
- Josting A, Rudolph C, Reiser M, et al. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. Ann Oncol 2002;13:1628-35
- Heider A, Niederle N. Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas. Anticancer Drugs 2001;12:725-9
- Diehl V, Sieber M, Ruffer U, et al. BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin's disease. The German Hodgkin's Lymphoma Study Group. Ann Oncol 1997;8:143-8
- Joint Formulary Committee. British National Formulary. 67th edn. BMJ Group and Pharmaceutical Press, 2014
- Department of Health NHS England. Reference costs 2012-13. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/261154/nhs_reference_costs_2012-13_acc.pdf. Accessed July 6, 2015
- Swinburn P, Shingler S, Acaster S, et al. Health utilities in relation to treatment response and adverse events in relapsed/refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Leuk Lymphoma 2015;56:1839-45
- Beusterien KM, Davies J, Leach M, et al. Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study. Health Qual Life Outcomes 2010;8:50
- Przepiorka D, van Besien K, Khouri I, et al. Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma. Ann Oncol 1999;10:527-32
- Office for National Statistics. Annual Survey of Hours and Earnings, 2013 Provisional Results. http://www.ons.gov.uk/ons/dcp171778_335027.pdf. Accessed July 6, 2015
- National Institute for Health and Care Excellence (NICE). Pemetrexed for the maintenance treatment of non-small-cell lung cancer. NICE technology appraisal guidance [TA190]. NICE technology appraisal guidance [TA190]. 2010. https://www.nice.org.uk/guidance/ta190. Accessed March 18, 2016
- National Institute for Health and Care Excellence (NICE). Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma. NICE technology appraisal guidance [TA268]. 2012. https://www.nice.org.uk/guidance/ta268. Accessed March 18, 2016
- National Institute for Health and Care Excellence (NICE). Breat cancer (advanced or metastatic – Iapatinib [ID20]. Appraising life-extending, end of life treatments. 2009. https://www.nice.org.uk/guidance/gid-tag387/resources/appraising-life-extending-end-of-life-treatments-paper22009. Accessed July 13, 2015
- Stewart G, Eddowes L, Hamerslag L, et al. The impact of NICE's end-of-life threshold on patient access to new cancer therapies in England And Wales. Value Health 2014;17:A6
- Josting A, Rueffer U, Franklin J, et al. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood 2000;96:1280-6
- Sureda A, Constans M, Iriondo A, et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol 2005;16:625-33
- European Medicines Agency. ADCETRIS® (brentuximab vedotin) European Public Assessment Report (EPAR). Procedure No. EMEA/H/C002455. 2012. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002455/WC500135054.pdf. Accessed March 18, 2016
- Chen R, Palmer JM, Tsai NC, et al. Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for Hodgkin lymphoma. Biol Blood Marrow Transplant 2014;20:1864-8
- Hanly P, Soerjomataram I, Sharp L. Measuring the societal burden of cancer: the cost of lost productivity due to premature cancer-related mortality in Europe. Int J Cancer 2015;136:E136-E45
- Claxton K, Walker S, Palmer S, et al. Appropriate perspectives for health care decisions. CHE Research Paper 54. York: University of York, Centre for Health Economics, 2010. http://www.york.ac.uk/che/pdf/rp54.pdf. Accessed March 21, 2016
- Drummond MF, Wilson DA, Kanavos P, et al. Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health Care 2007;23:36-42
- Battisti WP, Wager E, Baltzer L, et al. Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP3. Ann Intern Med 2015;163:461-4